RNXT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
RenovoRx Inc (RNXT) is not a strong buy at this moment for a beginner investor with a long-term horizon. The technical indicators suggest a bearish trend, and the company's financials, while showing some improvement in net income, still reflect a lack of profitability. Additionally, there are no strong trading signals or significant positive catalysts to justify immediate investment.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 26.653, and moving averages are bearish with SMA_200 > SMA_20 > SMA_5. The stock is trading near its key support level of 0.871, with resistance levels at 1.004 and 1.046.
RenovoRx's TAMP therapy platform for pancreatic cancer has been accepted for presentation at the 2026 Society of Interventional Radiology Annual Meeting, which could increase visibility. Analyst coverage initiated with a Buy rating and an $8 price target highlights potential long-term upside.
The company's financials reflect a lack of profitability, with a net loss of -$2.91M in Q3 2025 and a declining EPS (-20% YoY). Technical indicators are bearish, and there is no significant trading activity from hedge funds, insiders, or Congress.
In Q3 2025, revenue remained flat at $266,000 YoY. Net income improved by 17.85% YoY but remains negative at -$2.91M. EPS declined by 20% YoY to -0.08, and gross margin stayed flat at 80.08%.
JonesResearch analyst Justin Walsh initiated coverage with a Buy rating and an $8 price target, citing the potential of RenovoCath for treating pancreatic cancer. However, this is a long-term outlook and does not align with the current bearish technical indicators.
